116 related articles for article (PubMed ID: 29779347)
1. [Clinical analysis of 70 chronic lymphocytic leukemia patients with trisomy 12 detected by FISH].
Lyu R; Li ZJ; Li H; Yi SH; Liu W; Wang TY; Xiong WJ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):387-391. PubMed ID: 29779347
[No Abstract] [Full Text] [Related]
2. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.
Woyach JA; Ruppert AS; Rai K; Lin TS; Geyer S; Kolitz J; Appelbaum FR; Tallman MS; Belch AR; Morrison VA; Larson RA; Byrd JC
J Clin Oncol; 2013 Feb; 31(4):440-7. PubMed ID: 23233702
[TBL] [Abstract][Full Text] [Related]
3. [Clinical efficacy and safety of chemoimmunotherapy with rituximab,fludarabine and cyclophosphamide for chronic lymphocytic leukemia].
Li F; Yi SH; Yu Z; Xing LJ; Xu Y; Qi JY; Zhao YZ; Li ZJ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):383-8. PubMed ID: 23688746
[TBL] [Abstract][Full Text] [Related]
4. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
Ladyzynski P; Molik M; Foltynski P
Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
[TBL] [Abstract][Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
Main C; Pitt M; Moxham T; Stein K
Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488
[TBL] [Abstract][Full Text] [Related]
6. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.
Byrd JC; Rai K; Peterson BL; Appelbaum FR; Morrison VA; Kolitz JE; Shepherd L; Hines JD; Schiffer CA; Larson RA
Blood; 2005 Jan; 105(1):49-53. PubMed ID: 15138165
[TBL] [Abstract][Full Text] [Related]
7. [Clinical analysis of fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of 43 cases of chronic lymphoblastic leukemia].
Wang TY; Yi SH; Wang Y; Lyu R; Wang Q; Deng SH; Sui WW; Fu MW; Huang WY; Liu W; An G; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2021 Jul; 42(7):543-548. PubMed ID: 34455740
[No Abstract] [Full Text] [Related]
8. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
[TBL] [Abstract][Full Text] [Related]
9. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
10. Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.
Li Z; Li F; Yi S; Gu Z; Yu Z; Xu Y; Feng X; Liu W; Zou D; Qi J; Zhan F; Qiu L
BMC Cancer; 2015 Jul; 15():555. PubMed ID: 26219471
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Rituximab for Patients with Chronic Lymphocytic Leukemia.
Li H; Xiong WJ; Liu HM; Yi SH; Lü R; Wang TY; Yu Z; Qiu LG; Li ZJ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Dec; 39(6):800-805. PubMed ID: 29338825
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia.
Chow KU; Kim SZ; von Neuhoff N; Schlegelberger B; Stilgenbauer S; Wunderle L; Cordes HJ; Bergmann L
Eur J Haematol; 2011 Nov; 87(5):426-33. PubMed ID: 21749447
[TBL] [Abstract][Full Text] [Related]
13. First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis.
Michallet AS; Cazin B; Bouvet E; Oberic L; Schlaifer D; Mosser L; Salles G; Coiffier B; Laurent G; Ysebaert L
J Geriatr Oncol; 2013 Apr; 4(2):141-7. PubMed ID: 24071539
[TBL] [Abstract][Full Text] [Related]
14. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
Del Poeta G; Del Principe MI; Consalvo MA; Maurillo L; Buccisano F; Venditti A; Mazzone C; Bruno A; Gianní L; Capelli G; Lo Coco F; Cantonetti M; Gattei V; Amadori S
Cancer; 2005 Dec; 104(12):2743-52. PubMed ID: 16284990
[TBL] [Abstract][Full Text] [Related]
15. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
Hallek M; Fischer K; Fingerle-Rowson G; Fink AM; Busch R; Mayer J; Hensel M; Hopfinger G; Hess G; von Grünhagen U; Bergmann M; Catalano J; Zinzani PL; Caligaris-Cappio F; Seymour JF; Berrebi A; Jäger U; Cazin B; Trneny M; Westermann A; Wendtner CM; Eichhorst BF; Staib P; Bühler A; Winkler D; Zenz T; Böttcher S; Ritgen M; Mendila M; Kneba M; Döhner H; Stilgenbauer S; ;
Lancet; 2010 Oct; 376(9747):1164-74. PubMed ID: 20888994
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
Herishanu Y; Goldschmidt N; Bairey O; Ruchlemer R; Fineman R; Rahimi-Levene N; Shvidel L; Tadmor T; Ariel A; Braester A; Shapiro M; Joffe E; Polliack A;
Haematologica; 2015 May; 100(5):662-9. PubMed ID: 25661442
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study.
Choi Y; Lee JH; Jung CW; Jo JC; Kim JS; Kim I; Park S; Cheong JW; Park SH; Kim SY; Lee HG
Korean J Intern Med; 2021 Jan; 36(1):194-204. PubMed ID: 32279477
[TBL] [Abstract][Full Text] [Related]
18. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
Fischer K; Cramer P; Busch R; Stilgenbauer S; Bahlo J; Schweighofer CD; Böttcher S; Staib P; Kiehl M; Eckart MJ; Kranz G; Goede V; Elter T; Bühler A; Winkler D; Kneba M; Döhner H; Eichhorst BF; Hallek M; Wendtner CM
J Clin Oncol; 2011 Sep; 29(26):3559-66. PubMed ID: 21844497
[TBL] [Abstract][Full Text] [Related]
19. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
[TBL] [Abstract][Full Text] [Related]
20. Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group.
Cramer P; Fink AM; Busch R; Eichhorst B; Wendtner CM; Pflug N; Langerbeins P; Bahlo J; Goede V; Schubert F; Döhner H; Stilgenbauer S; Dreger P; Kneba M; Böttcher S; Mayer J; Hallek M; Fischer K
Leuk Lymphoma; 2013 Aug; 54(8):1821-2. PubMed ID: 23631654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
